news-3
news-3
news-3

Biotechnology's exclusive technology development of gut microbiota

In the domain of new drug development, the company has obtained two new drug  permit licenses from the ministry of health and welfare: “MS-20” and “Herbiron.” Also successfully established multiple microbial pharmaceutical technology platforms, achieving notable breakthrough in the biotechnology field, recognized with various prestigious awards and professional accolades, including the Biotechnology Medical Quality Award and the Biomedical Innovation Award. Concurrently, Microbio remains steadfast in its commitment to professional and rigorous R&D management. By leveraging a premier research and development team, the company continues to develop high-quality medical and health products, including patented, innovative flagship products such as Tien Chun Bao, premium enzymes, and the Li Shizhen Six Flavor Compound.

Shareholder/Investor Area

Microbio Group not only focuse on new drug development but also actively engaged in high-end medical devices, functional foods, organic and Innocuous agriculture, and biotech venture capital. Continuing expand the biotech business footprint and collaborates with domestically and internationally renowned research institutions, major global pharmaceutical companies and upstream and downstream biotech firms. Upholding to the corporate culture of “humble yet proactive, and practical yet innovative,” Microbio Group is committed to diligent and prudent, with a pragmatic approach and steady progress towards internationalization.

Join us! Challenge yourself to achieve an extraordinary future!

We will post the latest vacancies and job descriptions on 104 Human Resources Bank, please submit your resume directly through 104 Human Resources Bank.
Or send your resume to our Human Resources mailbox.hr@microbio.com.tw